Recent Research Analysts’ Ratings Updates for Marinus Pharmaceuticals (MRNS)

Marinus Pharmaceuticals (NASDAQ: MRNS) has recently received a number of price target changes and ratings updates:

• 10/4/2024 – Marinus Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 9/30/2024 – Marinus Pharmaceuticals was upgraded by analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating.
• 9/26/2024 – Marinus Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 9/24/2024 – Marinus Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $13.00 price target on the stock.
• 9/23/2024 – Marinus Pharmaceuticals was upgraded by analysts at Oppenheimer Holdings Inc. from a “market perform” rating to an “outperform” rating. They now have a $6.00 price target on the stock.
• 9/23/2024 – Marinus Pharmaceuticals had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $10.00 price target on the stock.
• 9/18/2024 – Marinus Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 9/16/2024 – Marinus Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $13.00 price target on the stock.
• 9/9/2024 – Marinus Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $13.00 price target on the stock.
• 9/9/2024 – Marinus Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 8/22/2024 – Marinus Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 8/14/2024 – Marinus Pharmaceuticals was downgraded by analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating.
• 8/14/2024 – Marinus Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 8/14/2024 – Marinus Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.

Marinus Pharmaceuticals Stock Up 5.2 %

Shares of MRNS traded up $0.09 during trading hours on Friday, reaching $1.74. The company’s stock had a trading volume of 233,051 shares, compared to its average volume of 1,100,651. The company has a 50 day moving average of $1.47 and a two-hundred day moving average of $2.16. The firm has a market cap of $95.56 million, a price-to-earnings ratio of -0.65 and a beta of 1.14. Marinus Pharmaceuticals, Inc. has a 1-year low of $1.05 and a 1-year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The business had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. During the same quarter in the prior year, the company posted ($0.61) earnings per share. As a group, analysts forecast that Marinus Pharmaceuticals, Inc. will post -1.93 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Point72 DIFC Ltd acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Marinus Pharmaceuticals during the second quarter worth approximately $64,000. AQR Capital Management LLC grew its stake in shares of Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at approximately $206,000. Finally, XTX Topco Ltd bought a new position in Marinus Pharmaceuticals in the 2nd quarter worth approximately $232,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.